Mercer Global Advisors
CTMX icon

Mercer Global Advisors’s CytomX Therapeutics CTMX Stock Holding History

Mercer Global Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.62K Buy
+699
New +$2.67K ﹤0.01% 5527

Other funds holding CTMX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Mercer Global Advisors's CTMX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 699 shares worth $2.62K. The stake represents ﹤0.01% of the portfolio and ranks #5527 among its holdings.

106 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Mercer Global Advisors held 699 shares of CytomX Therapeutics worth $2.62K as of Q2 2026.
  • CytomX Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5527 holding.
  • 106 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.